EVERY person has unique DNA sequence in their genome. Researchers at the University of Copenhagen and the labs for CRM in Cambridge in molecular biology have quantified that these differences in the genes associated with the drug mean that the drugs are selected.
In a new study that was published in the scientific journal Cell, they looked at certain receptors (GPCRs) in the human cell. These are the main targets of protein receptors, the largest marketed group of medicine modernized. Extracting data by the extent that they exist in mutations present in GPCR-derived drug targets, and investigating which of these mutations could have an effect on the therapeutic effect of the drug.
“We estimate that the average 3% population has receptors that contain mutations that alter the drug’s effect!” Says the study’s lead author, Alexander Hauser, Ph.D., the design department. Own pharmaceuticals and pharmacology from the University of Copenhagen. ,
“This could mean that the drug works less efficiently, but it may also mean that the drug is not acting at all or affecting patients negatively,” said Madan Babu, the last study of the MRC author’s laboratory for molecular biology. Cambridge hurts Hauser has done research this.
The researchers analyzed mutations in human GPCRs using genome sequencing data from the Genome 1000 project with approximately 2500 participants project owls from data exom-more than 60,000 participants.
They then use structural data to identify critical areas in the GPCR to find out which of the drug mutation most likely will change !.
“3% of the affected population is on average, which is a lot important for recipients of some important ones: for example, relevant mutations affect 69% of GLP-1 receptors, dies of diabetes medications and cases controlled in 86% GLP1 receptors. CNR2 receptor humans are being used as medications to relieve nausea induced by chemotherapy, but of course they do not know the genome and therefore each person’s estimates are based on the data, “he says. Alexander Hauser.
The results and their researchers use 279 GPCR drugs at the National Health Service in the UK to estimate how much money is spent on low or zero medication with no effect on sales data.
According to a prudent estimate, they estimate that the National Health Service of the UK supports at least 14 million pounds a year among the number of people considering both mutations in an important pressure of sites of the gene recipient.
“The prevalence of potential effects of and variations in drug response among individuals is a strong argument for this area and future research in Sind is a good example of why medicine could be personalized the right way to die.” says Hauser
